Jayne Gurtler

562 total citations
14 papers, 332 citations indexed

About

Jayne Gurtler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jayne Gurtler has authored 14 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Jayne Gurtler's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Jayne Gurtler is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Jayne Gurtler collaborates with scholars based in United States, Germany and Belgium. Jayne Gurtler's co-authors include Keith Stuart, Weijing Sun, Yihuan Xu, Richard S. Finn, Rakesh K. Jain, Adarsh Joshi, Mary F. Mulcahy, Dan G. Duda, F. Warren Nugent and Andrew X. Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Jayne Gurtler

14 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jayne Gurtler United States	7	188	120	98	82	68	14	332
Marco Imperatori Italy	10	273 1.5×	62 0.5×	121 1.2×	75 0.9×	111 1.6×	13	424
Fa-Chyi Lee United States	9	193 1.0×	85 0.7×	156 1.6×	79 1.0×	124 1.8×	24	385
Nicolas Moosmann Germany	12	449 2.4×	107 0.9×	216 2.2×	89 1.1×	45 0.7×	39	512
Wen-Son Hsieh United States	6	177 0.9×	56 0.5×	138 1.4×	75 0.9×	135 2.0×	9	329
Wanda Honeycutt United States	9	270 1.4×	54 0.5×	115 1.2×	33 0.4×	106 1.6×	20	363
Cindy Marando United States	5	151 0.8×	101 0.8×	76 0.8×	64 0.8×	116 1.7×	7	300
Benjamin Bonhomme France	8	131 0.7×	37 0.3×	81 0.8×	46 0.6×	45 0.7×	15	261
Gennaro Palmiotti Italy	9	163 0.9×	42 0.3×	105 1.1×	33 0.4×	74 1.1×	22	332
G. Atalay Belgium	7	182 1.0×	40 0.3×	72 0.7×	17 0.2×	63 0.9×	12	317
Karen Giselle Chee United States	7	182 1.0×	49 0.4×	163 1.7×	69 0.8×	102 1.5×	9	380

Countries citing papers authored by Jayne Gurtler

Since Specialization

Citations

This map shows the geographic impact of Jayne Gurtler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayne Gurtler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayne Gurtler more than expected).

Fields of papers citing papers by Jayne Gurtler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayne Gurtler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayne Gurtler. The network helps show where Jayne Gurtler may publish in the future.

Co-authorship network of co-authors of Jayne Gurtler

This figure shows the co-authorship network connecting the top 25 collaborators of Jayne Gurtler. A scholar is included among the top collaborators of Jayne Gurtler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayne Gurtler. Jayne Gurtler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Rajan, Arun, Jhanelle E. Gray, Siddhartha Devarakonda, et al.. (2019). Phase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC. Annals of Oncology. 30. v493–v494. 1 indexed citations

2.

Kelly, Karen, J. R. Infante, Nicholas Iannotti, et al.. (2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Open Repository and Bibliography (University of Liège). 1 indexed citations

3.

Goldstein, Lori J., Jayne Gurtler, Salvatore A. Del Prete, et al.. (2014). Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer. 14(6). 396–404. 14 indexed citations

4.

Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations

5.

Rixe, Olivier, John Sarantopoulos, Chung-Tsen Hsueh, et al.. (2013). Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(6_suppl). 126–126. 1 indexed citations

6.

Ko, Andrew H., Hagop Youssoufian, Jayne Gurtler, et al.. (2011). A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Investigational New Drugs. 30(4). 1597–1606. 49 indexed citations

7.

Zhu, Andrew X., RS Finn, Jayne Gurtler, et al.. (2010). A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 28(15_suppl). 4083–4083. 23 indexed citations

8.

Gurtler, Jayne, Laura H. Goldstein, S. Tjulandin, et al.. (2005). Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens. Journal of Clinical Oncology. 23(16_suppl). 625–625. 22 indexed citations

9.

Gurtler, Jayne, Joachim von Pawel, C. Harris Spiridonidis, et al.. (2004). An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59–8862) in patients with taxane-resistant non-small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7136–7136. 6 indexed citations

10.

Gurtler, Jayne, Joachim von Pawel, C. Harris Spiridonidis, et al.. (2004). An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59–8862) in patients with taxane-resistant non-small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7136–7136. 1 indexed citations

11.

Kemeny, Nancy E., Carlos A. Garay, Jayne Gurtler, et al.. (2004). Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer. Journal of Clinical Oncology. 22(23). 4753–4761. 66 indexed citations

12.

McBurney, Elizabeth I., et al.. (2002). CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. Journal of the American Academy of Dermatology. 46(3). 441–443. 23 indexed citations

13.

Liebmann, James & Jayne Gurtler. (1995). Combination intraventricular therapy with thiotepa and cytarabine in meningeal carcinomatosis due to breast cancer. Anti-Cancer Drugs. 6(1). 40–44. 2 indexed citations

14.

Gurtler, Jayne. (1979). [Acupuncture, Electropuncture and lasers in the treatment of low back pain (author's transl)].. PubMed. 68(5). 149–51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact